Aeirtec

Executive Summary

Aeirtec is a UK-based biotechnology company founded in 2017 that specializes in ultrasensitive biomarker analysis. Its proprietary technology combines high-sensitivity multiplex immunoassays with next-generation sequencing (NGS) for gene expression, enabling quantification of protein markers at femtomolar concentrations. This platform offers exceptional sensitivity for detecting low-abundance biomarkers, which is critical for early disease detection, monitoring therapeutic response, and advancing precision medicine in respiratory and immunological disorders. The company provides these services to support clinical studies and research collaborations, positioning itself as a key enabler for biopharma and academic partners seeking to unlock novel biomarkers. The global ultrasensitive biomarker market is growing rapidly, driven by demand for earlier diagnosis and more effective targeted therapies. Aeirtec's unique capability to measure proteins at extremely low levels could significantly impact drug development and patient stratification, particularly in areas like asthma, COPD, and autoimmune diseases where traditional assays lack sensitivity. While the company remains private and has not disclosed funding rounds or revenue, its technology platform represents a potential competitive advantage. If Aeirtec can secure strategic partnerships or generate compelling validation data, it may attract further investment and accelerate commercialization. The upcoming periods could see collaboration announcements or clinical study results that validate its platform and drive adoption.

Upcoming Catalysts (preview)

• Q3 2026Strategic Collaboration with a Major Pharma or Diagnostics Company60% success
• Q4 2026Publication of Sensitivity and Specificity Data from a Clinical Study65% success
• TBDExpansion of Service Menu into New Therapeutic Areas (e.g., Oncology or Neurology)50% success